TY - JOUR
T1 - A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors
AU - Hauert, Sabine
AU - Berman, Spring
AU - Nagpal, Radhika
AU - Bhatia, Sangeeta N.
N1 - Funding Information:
The authors are grateful to Dr. Fleming for her help in reviewing this manuscript. Dr. Hauert and Dr. Bhatia acknowledge support from the Human Frontier Science Program , The Marie-D. & Pierre Casimir-Lambert Fund , and NIH grant # U54 CA151884 . Dr. Berman acknowledges support from National Science Foundation Expeditions in Computing grant CCF-0926148 . Dr. Bhatia is an HHMI investigator. This work was supported in part by the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute. The authors wish to dedicate this paper to the memory of Officer Sean Collier for his caring service to the MIT community and for his sacrifice.
Funding Information:
Radhika Nagpal is a professor in Computer Science, in the Harvard School of Engineering and Applied Sciences and core faculty member of the Wyss Institute for Biologically Inspired Engineering, where she co-lead the BioRobotics Platform. She is also affiliated with the Department of Systems Biology at Harvard Medical School. She was a graduate student and postdoc lecturer at the MIT CSAIL, a member of the Amorphous Computing Group and a Bell Labs GRPW graduate fellow. She received the Microsoft New Faculty Fellowship Award, NSF Career Award, the Thomas D. Cabot Associate Professor Chair, the Borg Early Career Award, and a Radcliffe Fellowship.
PY - 2013/12
Y1 - 2013/12
N2 - Targeted nanoparticles are increasingly being engineered for the treatment of cancer. By design, they can passively accumulate in tumors, selectively bind to targets in their environment, and deliver localized treatments. However, the penetration of targeted nanoparticles deep into tissue can be hindered by their slow diffusion and a high binding affinity. As a result, they often localize to areas around the vessels from which they extravasate, never reaching the deep-seeded tumor cells, thereby limiting their efficacy. To increase tissue penetration and cellular accumulation, we propose generalizable guidelines for nanoparticle design and validate them using two different computer models that capture the potency, motion, binding kinetics, and cellular internalization of targeted nanoparticles in a section of tumor tissue. One strategy that emerged from the models was delaying nanoparticle binding until after the nanoparticles have had time to diffuse deep into the tissue. Results show that nanoparticles that are designed according to these guidelines do not require fine-tuning of their kinetics or size and can be administered in lower doses than classical targeted nanoparticles for a desired tissue penetration in a large variety of tumor scenarios. In the future, similar models could serve as a testbed to explore engineered tissue-distributions that arise when large numbers of nanoparticles interact in a tumor environment.
AB - Targeted nanoparticles are increasingly being engineered for the treatment of cancer. By design, they can passively accumulate in tumors, selectively bind to targets in their environment, and deliver localized treatments. However, the penetration of targeted nanoparticles deep into tissue can be hindered by their slow diffusion and a high binding affinity. As a result, they often localize to areas around the vessels from which they extravasate, never reaching the deep-seeded tumor cells, thereby limiting their efficacy. To increase tissue penetration and cellular accumulation, we propose generalizable guidelines for nanoparticle design and validate them using two different computer models that capture the potency, motion, binding kinetics, and cellular internalization of targeted nanoparticles in a section of tumor tissue. One strategy that emerged from the models was delaying nanoparticle binding until after the nanoparticles have had time to diffuse deep into the tissue. Results show that nanoparticles that are designed according to these guidelines do not require fine-tuning of their kinetics or size and can be administered in lower doses than classical targeted nanoparticles for a desired tissue penetration in a large variety of tumor scenarios. In the future, similar models could serve as a testbed to explore engineered tissue-distributions that arise when large numbers of nanoparticles interact in a tumor environment.
KW - Cancer
KW - Modeling
KW - Nanoparticle
KW - Systems nanotechnology
KW - Targeting
KW - Tissue penetration
UR - http://www.scopus.com/inward/record.url?scp=84895067794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895067794&partnerID=8YFLogxK
U2 - 10.1016/j.nantod.2013.11.001
DO - 10.1016/j.nantod.2013.11.001
M3 - Article
C2 - 25009578
AN - SCOPUS:84895067794
SN - 1748-0132
VL - 8
SP - 566
EP - 576
JO - Nano Today
JF - Nano Today
IS - 6
ER -